The COPD Foundation recently welcomed CSL Behring to the Industry Expert Forum for PIVOT, which stands for Patient-Inspired Validation of Outcome Tools. Its goal is to literally pivot so that lung disease patients have more of a say in how treatments are evaluated for effectiveness.
In other words, a treatment ought to correct or improve what patients value most. That’s why the COPD Foundation is developing “a patient-centric coordination framework for pharmacological and non-pharmacological approaches in COPD, bronchiectasis, and other chronic lung diseases.”
The effort will draw upon patients’ lived experience to identify meaningful aspects of health, such as how a patient feels and functions, in creating an instrument to measure treatment effects.
“Delivering life-saving medicines to patients in need is our prime goal. To do so, taking into account the patients’ perspective and agreeing on relevant outcome measures with all stakeholders is key.”, said Dr. Lars Groenke, Vice President, R&D Lead for CSL’s Respiratory Therapeutic Area.
The COPD Foundation said CSL Behring will bring its valuable experience using computed tomography (CT) lung density as a measure of emphysema in clinical trials. CSL Behring is a global biotech company that develops and manufactures medicines for people who have rare and serious diseases.
“It’s an exciting time for the Foundation as we forge a path toward a new paradigm that focuses on the evaluation of patient-centered treatment benefit for people with chronic lung disease. We look forward to working alongside patients, patient advocates, researchers, health care professionals, and industry experts like CSL Behring,” Alan Hamilton, PIVOT Steering Committee Chair and COPD Foundation Senior Director of Research, said in an announcement.
The COPD (Chronic Obstructive Pulmonary Disease) Foundation was established to improve the lives of people with COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease through initiatives that expand services and speed innovations which will make treatment more effective and affordable. The organization takes action through scientific research, education, advocacy and awareness with the goal of disease prevention, slowed progression and ultimately a cure.
